Drug Design and Analytical Chemistry


  • Ramsbeck D, Hamann A, Richter G, Schlenzig D, Geissler S, Nykiel V, Cynis H, Schilling S, Buchholz M. Structure-guided design, synthesis and characteriza­tion of next-generation meprin β inhibitors. Journal of medicinal chemistry 61 (2018), 10, S. 4578-4592. dx.doi.org/10.1021/acs.jmedchem.8b00330
  • Schneider T, Hahn-Löbmann S, Stephan A, Schulz S, Giritch A, Naumann M, Kleinschmidt M, Tusé D, Gleba Y. Plant-made Salmonella bacteriocins salmocins for control of Salmonella pathovars. Scientific Reports 8 (2018), Art: 4078. dx.doi.org/10.1038/s41598-018-22465-9
  • Tan K, Jäger C, Schlenzig D, Schilling S, Buchholz M, Ramsbeck D. Tertiary-amine-based inhibitors of the astacin protease meprin α. ChemMedChem 13 (2018), 16, S. 1619-1624. dx.doi.org/10.1002/cmdc.201800300
  • Ramsbeck D, Hamann A, Schlenzig D, Schilling S, Buchholz M. First insight into structure-activity relationships of selective Meprin ß inhibitors. Bioorganic & Medicinal Chemistry Letters. 27 (2017), 11, S. 2428-2431. dx.doi.org/10.1016/j.bmcl.2017.04.012
  • Stephan A, Hahn-Löbmann S, Rosche F, Buchholz M, Giritch A, Gleba Y. Simple purification of Nicotiana benthamiana-produced recombinant colicins: High-yield recovery of purified proteins with minimum alkaloid content supports the suitability of the host for manufacturing food additives. International Journal of Molecular Sciences. 19 (2017). 1, Art. 95, 13 S. dx.doi.org/10.3390/ijms19010095
  • Hielscher-Michael S, Griehl C, Buchholz M, Demuth HU, Arnold N, Wessjohann LA. Natural products from microalgae with potential against Alzheimer’s disease: sulfolipids are potent glutaminyl cyclase inhibitors. Mar Drugs. 2016 Nov 2;14(11). pii: E203. dx.doi.org/10.3390/md14110203
  • Kleinschmidt M, Schoenfeld R, Göttlich C, Bittner D, Metzner JE, Leplow B, Demuth HU. Characterizing aging, mild cognitive impairment, and Dementia with blood-based biomarkers and neuropsychology. Journal of Alzheimer‘s disease. 50 (2016), 1, S. 111-26. dx.doi.org/10.3233/JAD-143189
  • Kleinschmidt M, Schoenfeld R, Göttlich C, Bittner D, Metzner JE, Leplow B, Demuth HU. Characterizing Aging, Mild Cognitive Impairment, and Dementia with Blood-Based Biomarkers and Neuropsychology. J Alzheimers Dis. 2015;50(1):111-26. DOI dx.doi.org/10.3233/JAD-143189
  • Ramsbeck, D.; Buchholz, M.; Koch, B.; Böhme, L.; Hoffmann, T.; Demuth, H.-U.; Heiser, U. Structure-activity relationships of benzimidazole-based glutaminyl cyclase inhibitors featuring a heteroaryl scaffold. J Med Chem (2013), 56, 6613–6625. DOI dx.doi.org/10.1021/jm4001709
  • Frost JL, Liu B, Kleinschmidt M, Schilling S, Demuth HU, Lemere CA. Passive immunization against pyroglutamate-3 amyloid-β reduces plaque burden in Alzheimer-like transgenic mice: a pilot study. Neurodegener Dis. (2012);10, 265-70, DOI dx.doi.org/10.1159/000335913
  • Koch, B.; Buchholz, M.; Wermann, M.; Heiser, U.; Schilling, S.; Demuth, H.-U. Probing secondary glutaminyl cyclase (QC) inhibitor interactions applying an in silico-modeling/site-directed mutagenesis approach: implications for drug development. Chemical biology & drug design (2012), 80, 937–946. DOI dx.doi.org/10.1111/cbdd.12046